In a patient with severe anemia and congenital heart disease on warfarin who develops altered mental status and decreased responsiveness, what is the most likely diagnosis?

Warfarin-Associated Intracerebral Hemorrhage (ICH)

The most likely diagnosis is warfarin-associated intracerebral hemorrhage (ICH), which is a life-threatening complication that occurs when severe anemia compounds the bleeding risk in anticoagulated patients, leading to altered mental status and decreased responsiveness.

Clinical Reasoning

This patient presents with the classic triad suggesting intracranial bleeding:

• Severe anemia (indicating active or recent hemorrhage)
• Warfarin therapy (increasing hemorrhage risk)
• Altered sensorium with decreased responsiveness (suggesting intracranial pathology)

Why ICH is the Primary Diagnosis

Warfarin significantly increases ICH risk and severity. Anticoagulant-related hemorrhages are associated with increased hematoma volume, hematoma expansion, and increased morbidity and mortality 1. The altered mental status and decreased responsiveness indicate neurological compromise from intracranial bleeding.

Severe anemia is both a marker and risk factor for bleeding complications. When hemoglobin falls below reference values (130 g/L for men, 120 g/L for women), the odds ratio for bleeding complications is 2.9, and when hemoglobin drops below 100 g/L, the complication risk increases 10-fold 2. The presence of severe anemia in this warfarin-treated patient strongly suggests active hemorrhage.

The combination is particularly dangerous. Admission anemia is independently associated with hemorrhagic expansion and poor outcomes in ICH patients 1. The deeper the anemia, the higher the risk of both bleeding and thrombotic complications 2.

Immediate Diagnostic Approach

Obtain emergent non-contrast head CT immediately to confirm ICH diagnosis, as rapid neuroimaging with CT or MRI is recommended in patients presenting with stroke-like symptoms 1.

Check coagulation studies urgently:

• INR (international normalized ratio)
• Complete blood count with hemoglobin/hematocrit
• Platelet count
• Prothrombin time/partial thromboplastin time 1

The INR value in warfarin-related hemorrhage may predict outcome, with elevated INR showing a dose-response relationship with poor outcomes 1.

Critical Pitfalls to Avoid

Do not assume INR alone predicts bleeding risk. Research shows that patients with bleeds had significantly lower hemoglobin (median 126 vs 135 g/L in controls) preceding the event, while INR remained mainly at target and only occasionally deviated, failing to detect the complication risk 2.

Do not delay reversal of anticoagulation. Warfarin has a duration of action of 2-5 days from a single dose, and effects of daily maintenance doses overlap 3. The anticoagulant effect persists even after stopping the drug, requiring active reversal with fresh frozen plasma (FFP) and vitamin K 1.

Beware of rebound warfarin toxicity. Even after INR correction with FFP, warfarin toxicity can recur because FFP has a shorter half-life than warfarin 4. Vitamin K administration is essential for sustained reversal.

Management Priorities

1. Secure airway and stabilize hemodynamics in this patient with decreased responsiveness
2. Reverse anticoagulation immediately with FFP and vitamin K 1
3. Obtain neurosurgical consultation for potential surgical intervention (EVD or craniotomy) 1
4. Serial head CT within 24 hours to evaluate for hemorrhage expansion 1
5. Correct severe anemia with transfusion as clinically indicated

The congenital heart disease adds complexity but does not change the immediate priority of diagnosing and managing life-threatening ICH in this anticoagulated patient with severe anemia and neurological deterioration.